Due to the dual role of PI3Ks in tumor and immune compartments, new therapeutic approaches combining PI3K inactivation with most recent immune check-point inhibitors, adoptive cell transfer therapy, and immunomodulatory agents have been developed. This evidence concerns the gene PIK3CA and neoplasm.